Michael S. Gordon

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 7 papers. Top paper: “CD8-targeted PET Imaging of Tumor Infiltrating T cells in Patients with Cancer: A Phase I First-in-Human Study of 89Zr-Df-IAB22M2C, a Radiolabeled anti-CD8 Minibody”.

CD8-targeted PET Imaging of Tumor Infiltrating T cells in Patients with Cancer: A Phase I First-in-Human Study of 89Zr-Df-IAB22M2C, a Radiolabeled anti-CD8 Minibody

Journal of Nuclear Medicine(2021)10.2967/jnumed.121.262485

N/A

3.7DataRank · unranked

124 citations

Raymond F. Gamache, Hasan Babazada, Matthew D. Hellmann, James J. Harding, Ron Korn +10 more

Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer

British Journal of Cancer(2020)10.1038/s41416-020-01041-x

N/A

2.6DataRank · unranked

90 citations

Michael S. Gordon, Monica Mita, Brian I. Rini, Vicky Makker, Teresa Macarulla +15 more

PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma

Nature Communications(2020)10.1038/s41467-020-19810-w

N/A

0.675DataRank · unranked

89 citations

Alain P. Algazi, Paolo A. Ascierto, Marcus O. Butler, Sunandana Chandra, Michael S. Gordon +10 more

Cabozantinib in Chemotherapy-Pretreated Metastatic Castration-Resistant Prostate Cancer: Results of a Phase II Nonrandomized Expansion Study

UNC Libraries(2020)10.17615/yxdm-6w50

N/A

0DataRank · unranked

0 citations

Christopher J. Sweeney, Frauke Schimmöller, Dana E. Rathkopf, Naomi B. Haas, Celestia S. Higano +16 more

A phase I/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancer

ESMO Open(2025)10.1016/j.esmoop.2025.104536

N/A

0DataRank · unranked

60 citations

Martin H. Voss, Hussein A. Tawbi, Michael S. Gordon, Scott S. Tykodi, Elaine T. Lam +13 more

Non‐Mosaic Trisomy 9: Further Delineation of the Clinical Phenotype

American Journal of Medical Genetics Part A(2025)10.1002/ajmg.a.64087

N/A

0DataRank · unranked

0 citations

Michael S. Gordon, Bradley D. Holbrook, Olivia Maher Trocki, Tabitha Poorvu, Christina Miller +7 more

Phase IB trial of high dose ascorbic acid + nab-paclitaxel + cisplatin + gemcitabine in patients with untreated metastatic pancreatic cancer

Redox Biology(2025)10.1016/j.redox.2025.103895

N/A

0DataRank · unranked

0 citations

S. Danielle. Legrand, Michael S. Gordon, Denise J. Roe, Betsy C. Wertheim, Kellen Olszewski +12 more